Kiadis Pharma N.V.

Who: Sanofi/Scribe Therapeutics What: Sanofi is partnering with the next-generation gene editing firm founded by Jennifer Doudna, one of the inventors of CRISPR-Cas9 genome editing, to advance its

Restructured and refocused Dutch cell therapy specialist Kiadis Pharma Netherlands BV has received the regulatory go-ahead from who from the US Food and Drug Administration (FDA) to conduct multiple

The European Medicines Agency today said it had recommended for EU-wide marketing approval seven new drugs, including two orphans – Roche's Polivy (polatuzumab vedotin), for treating diffuse large

Two companies – Kiadis Pharma and Aradigm – have formally withdrawn pan-EU marketing authorization applications (MAAs) after they were told these were likely to be rejected. A third company, Actelion,